Clinical Trials Sponsored by Atopic Dermatitis and Vaccinia Network

Total 48 results

National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis and Vaccinia Network

Completed

Identifying Risk Factors for Eczema Herpeticum in Individuals With Atopic Dermatitis

Atopic Dermatitis | Eczema Herpeticum

Germany
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis and Vaccinia Network

Completed

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

Atopic Dermatitis

United States
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

Dermatitis, Atopic

United States
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Atopic Dermatitis (AD) and Food Allergy

Atopic Dermatitis (AD) | Non-atopic Healthy Controls

United States
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Terminated

Targeted Investigation of Microbiome Elimination (TIME-1)

Atopic Dermatitis

United States
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Targeted Microbiome Transplant in Atopic Dermatitis

Atopic Dermatitis (AD)

United States
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Registry for the Atopic Dermatitis Research Network

Atopic Dermatitis | Eczema Herpeticum

United States
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Interferon Responses in Eczema Herpeticum (ADRN-01)

Atopic Dermatitis | Herpes Simplex Infections | Eczema Herpeticum | Eczema Vaccinatum

United States
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

Atopic Dermatitis

United States
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

ADRN Barrier/Immunoprofiling Exploratory Pilot Study

Dermatitis | Eczema | Dermatitis, Atopic | Non-atopic Healthy Controls

United States
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.; Atopic Dermatitis Research Network

Completed

Etiology of Eczema Herpeticum (EH)

Eczema Herpeticum

United States
National Institute of Allergy and Infectious Diseases...
Sanofi; Regeneron Pharmaceuticals; Rho Federal Systems Division, Inc.; Atopic Dermatitis...

Terminated

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

Atopic Dermatitis (AD)

United States
International Atomic Energy Agency
International Network for Cancer Treatment and Research

Unknown

Resource-sparing Post-mastectomy Radiotherapy in Breast Cancer

Breast Cancer

Cuba, Egypt, Ghana, Morocco, Nigeria, Pakistan, Peru, Turkey
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines; HIV Vaccine Trials Network; IPPOX Foundation

Completed

Safety and Immune Response to a Clade C DNA HIV Vaccine (HVTN111)

HIV Infections

South Africa, Zambia, Tanzania
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network; HIV Prevention Trials Network

Completed

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants

HIV Infections

United States
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); HIV Prevention...

Completed

Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19

COVID-19 | SARS-CoV-2

United States, Zimbabwe, Malawi, Peru, South Africa, Zambia
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants (HVTN143)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Terminated

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

HIV Infections

United States, Peru
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

HIV Infections

United States, South Africa
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials

HIV Infections

United States, South Africa, Peru, Brazil
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants (HVTN 135)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults

HIV Infections

South Africa
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); Biofabri, S.L

Recruiting

Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa (HVTN605A5421)

Tuberculosis | HIV I Infection

South Africa
AlphaVax, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Completed

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

HIV Infections

United States, Botswana, South Africa
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); EuroVacc Foundation

Completed

Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults

HIV Infections

Switzerland
AlphaVax, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Completed

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

HIV Infections

United States, South Africa
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); AIDS Clinical... and other collaborators

Recruiting

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

HIV Infection

Malawi, Botswana, South Africa, Zimbabwe
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); AIDS Clinical... and other collaborators

Active, not recruiting

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study

HIV Infection

United States, Peru, Brazil
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network; IPPOX Foundation; Center for HIV/AIDS Vaccine Immunology...

Withdrawn

Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults

HIV Infections
National Institute of Allergy and Infectious Diseases...
Centers for Disease Control and Prevention; International AIDS Vaccine Initiative and other collaborators

Withdrawn

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

HIV Infections
Vir Biotechnology, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Recruiting

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

HIV I Infection

United States, South Africa
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network; IPPOX Foundation; CHAVI; MHRP

Completed

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

HIV Infections

United States, Switzerland
National Institute of Allergy and Infectious Diseases...
Bavarian Nordic; HIV Vaccine Trials Network; Pharmexa-Epimmune

Completed

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

HIV Infections

United States
Merck Sharp & Dohme LLC
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Completed

A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)

HIV Infections | HIV-1
International AIDS Vaccine Initiative
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaborators

Completed

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

HIV Infections

United States, Kenya, Rwanda, South Africa
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company; HIV Vaccine Trials Network

Completed

Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (HVTN107)

HIV Infections

South Africa, Mozambique, Zimbabwe
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaborators

Active, not recruiting

Evaluating the Safety and Immunogenicity of HIV-1 Vaccines Based on Chimpanzee Serotypes of Ad Expressing Clade C gp140 and a CH505TF gp120 Protein Boost in Healthy, HIV- Uninfected Adult Participants (HVTN139)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...
Fred Hutchinson Cancer Center; International AIDS Vaccine Initiative; HIV Vaccine... and other collaborators

Active, not recruiting

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Department of Health and Human Services; HIV Vaccine Trials Network; Inovio Pharmaceuticals and other collaborators

Active, not recruiting

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

HIV Infections

United States, South Africa
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network; IPPOX Foundation; EuroVacc Foundation; Global Solutions...

Withdrawn

Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa

HIV Infections
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Bill and Melinda Gates Foundation; Medical Research Council; Sanofi... and other collaborators

Completed

A Safety and Immune Response Study of 2 Experimental HIV Vaccines

HIV Infection

South Africa
National Institute of Allergy and Infectious Diseases...
University of Maryland, Baltimore; Duke University; HIV Vaccine Trials Network... and other collaborators

Withdrawn

Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants

HIV Infections

Clinical Trials Sponsored by Atopic Dermatitis and Vaccinia Network

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations